BeiGene Ltd.
(NASDAQ : BGNE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -1.24%63.151.0%$510.50m
AMGNAmgen, Inc. -4.02%225.591.3%$451.51m
BIIBBiogen, Inc. -2.14%278.141.4%$375.15m
ILMNIllumina, Inc. -2.27%319.583.5%$322.74m
VRTXVertex Pharmaceuticals, Inc. -2.07%229.061.9%$273.01m
REGNRegeneron Pharmaceuticals, Inc. -3.17%345.282.6%$238.76m
EXASEXACT Sciences Corp. -2.83%89.5724.0%$223.37m
ALXNAlexion Pharmaceuticals, Inc. -3.02%105.272.0%$170.84m
AAgilent Technologies, Inc. -0.92%88.251.6%$130.79m
INCYIncyte Corp. -1.92%76.742.5%$127.16m
BMRNBioMarin Pharmaceutical, Inc. 0.61%86.154.3%$108.27m
SRPTSarepta Therapeutics, Inc. -1.14%112.3914.6%$108.00m
SGENSeattle Genetics, Inc. -1.54%113.576.1%$103.89m
BLUEbluebird bio, Inc. -2.74%87.2614.2%$86.40m
DERMDermira, Inc. -0.27%18.713.8%$83.32m

Company Profile

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.